Operator: Ladies and gentlemen, thank you for standing by. At this time, I would like to welcome everyone to the Organon First Quarter 2023 Earnings Conference Call.
First quarter 2023 revenue of $1,538 millionFirst quarter 2023 diluted earnings per share of $0.69 and non-GAAP Adjusted diluted earnings per share of $1.08Both reported and non-GAAP Adjusted diluted earnings per share include a negative impact of $0.03 per share for acquired in-process research and development (IPR.
The healthcare industry outlook is currently uncertain due to a combination of factors such as economic troubles, a shortage of healthcare workers, and the ongoing COVID-19 pandemic.
The announcement comes after Carlyle announced a strategic partnership with VLCC through the acquisition of majority stake in the company in December 2022.